The results of this present retrospective investigation in 153 consequentially treated GBM patients displayed that a pretreatment CRP/Alb <0.75 was linked with significantly superior OS (P < 0.001) outcomes than a CRP/Alb ≥0.75 and, therefore, offered an attractive prognostic incentive for this inflammation-based parameter in further stratification of such patients into two distinct survival groups. Here, CRP is linked to glioblastoma.